JP7250519B2 - Ｐｄ－１及び４－１ｂｂの融合タンパク質 - Google Patents

Ｐｄ－１及び４－１ｂｂの融合タンパク質 Download PDF

Info

Publication number
JP7250519B2
JP7250519B2 JP2018549452A JP2018549452A JP7250519B2 JP 7250519 B2 JP7250519 B2 JP 7250519B2 JP 2018549452 A JP2018549452 A JP 2018549452A JP 2018549452 A JP2018549452 A JP 2018549452A JP 7250519 B2 JP7250519 B2 JP 7250519B2
Authority
JP
Japan
Prior art keywords
cells
fusion protein
nucleic acid
amino acid
host cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018549452A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512251A5 (enExample
JP2019512251A (ja
Inventor
ノエスナー，エルフリーデ
シュレンカー，ラモナ
ヴァイツ，シュテファン
Original Assignee
ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー）
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー） filed Critical ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー）
Publication of JP2019512251A publication Critical patent/JP2019512251A/ja
Publication of JP2019512251A5 publication Critical patent/JP2019512251A5/ja
Priority to JP2023045262A priority Critical patent/JP7746323B2/ja
Application granted granted Critical
Publication of JP7250519B2 publication Critical patent/JP7250519B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2018549452A 2016-03-23 2017-03-23 Ｐｄ－１及び４－１ｂｂの融合タンパク質 Active JP7250519B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023045262A JP7746323B2 (ja) 2016-03-23 2023-03-22 Ｐｄ－１及び４－１ｂｂの融合タンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
LU93006 2016-03-23
LULU93006 2016-03-23
PCT/EP2017/056931 WO2017162797A1 (en) 2016-03-23 2017-03-23 Fusion proteins of pd-1 and 4-1bb

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023045262A Division JP7746323B2 (ja) 2016-03-23 2023-03-22 Ｐｄ－１及び４－１ｂｂの融合タンパク質

Publications (3)

Publication Number Publication Date
JP2019512251A JP2019512251A (ja) 2019-05-16
JP2019512251A5 JP2019512251A5 (enExample) 2019-09-19
JP7250519B2 true JP7250519B2 (ja) 2023-04-03

Family

ID=55702054

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018549452A Active JP7250519B2 (ja) 2016-03-23 2017-03-23 Ｐｄ－１及び４－１ｂｂの融合タンパク質
JP2023045262A Active JP7746323B2 (ja) 2016-03-23 2023-03-22 Ｐｄ－１及び４－１ｂｂの融合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023045262A Active JP7746323B2 (ja) 2016-03-23 2023-03-22 Ｐｄ－１及び４－１ｂｂの融合タンパク質

Country Status (8)

Country Link
US (3) US11365237B2 (enExample)
EP (2) EP4286522A3 (enExample)
JP (2) JP7250519B2 (enExample)
CN (1) CN109195985B (enExample)
AU (1) AU2017236069B2 (enExample)
CA (1) CA3017036A1 (enExample)
ES (1) ES2962588T3 (enExample)
WO (1) WO2017162797A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180029201A (ko) 2015-05-18 2018-03-20 티씨알2 테라퓨틱스 인크. 융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법
EP4286522A3 (en) * 2016-03-23 2024-02-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins of pd-1 and 4-1bb
JP7291396B2 (ja) 2016-11-22 2023-06-15 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
CA3038150A1 (en) * 2016-12-22 2018-06-28 Windmil Therapeutics, Inc. Compositions and methods for modulating the immune system
WO2018181390A1 (ja) 2017-03-31 2018-10-04 東亞合成株式会社 Ｐｄ－１シグナル配列を有する抗腫瘍ペプチドおよびその利用
SG11202013170RA (en) * 2018-07-11 2021-01-28 Kahr Medical Ltd Pd1-4-1bbl variant fusion protein and methods of use thereof
KR102351041B1 (ko) * 2018-12-19 2022-01-13 한국화학연구원 인간 lrrc24 단백질 유래 세포막 투과 도메인
WO2020146423A1 (en) * 2019-01-07 2020-07-16 Thomas Jefferson University Multi-functional fusion proteins and uses thereof
EP3999079A4 (en) * 2019-07-19 2024-04-03 Memorial Sloan Kettering Cancer Center Fusion polypeptide for immunotherapy
CN115956086A (zh) * 2020-05-06 2023-04-11 萨摩亚商柏沛生医股份有限公司 用于针对癌症及传染病的免疫疗法的融合蛋白
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
WO2023025779A1 (en) * 2021-08-25 2023-03-02 Medigene Immunotherapies Gmbh Combination of antigen specific t cell receptors and chimeric co-stimulatory receptors
JP2025527657A (ja) * 2022-08-23 2025-08-22 メディジーン イミュノテラピーズ ゲーエムベーハー Ｎｙ－ｅｓｏ－１特異的ｔ細胞受容体とキメラ共刺激受容体との組み合わせ物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141520A1 (es) * 2011-07-29 2014-11-17 Univ Pennsylvania Receptores coestimuladores de cambio
KR101471647B1 (ko) * 2011-10-26 2014-12-11 국립암센터 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
CN105518018B (zh) * 2013-03-15 2020-04-03 细胞基因公司 修饰的t淋巴细胞
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
BR112015027567B1 (pt) 2013-05-03 2024-02-20 Ohio State Innovation Foundation Polipeptídeo, sequência de ácido nucleico isolada, vetor, método de obtenção de célula, uso de uma célula
WO2015142675A2 (en) * 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
SG10201900455YA (en) * 2014-07-24 2019-02-27 Bluebird Bio Inc Bcma chimeric antigen receptors
US20170209492A1 (en) * 2014-07-31 2017-07-27 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
CA2973529A1 (en) * 2015-01-26 2016-08-04 Cellectis Cll1-specific multi-chain chimeric antigen receptor
AU2015380397B2 (en) * 2015-01-31 2021-10-21 The Trustees Of The University Of Pennsylvania Compositions and methods for T cell delivery of therapeutic molecules
CA2976684C (en) * 2015-03-02 2024-03-05 Innovative Cellular Therapeutics CO., LTD. Reducing immune tolerance induced by pd-l1
CN107531805A (zh) * 2015-03-05 2018-01-02 弗雷德哈钦森癌症研究中心 免疫调节融合蛋白及其用途
KR20180029201A (ko) * 2015-05-18 2018-03-20 티씨알2 테라퓨틱스 인크. 융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법
CN104829733B (zh) 2015-05-25 2018-06-05 广州百暨基因科技有限公司 抗原结合单元稳定的嵌合抗原受体及制备方法与应用
PT3310805T (pt) * 2015-06-19 2021-05-19 Kobold Sebastian Proteínas de fusão pd-1-cd28 e a sua utilização em medicina
HK1255637A1 (zh) * 2015-06-29 2019-08-23 The Johns Hopkins University 免疫检查点嵌合受体疗法
EP3344284A1 (en) * 2015-09-04 2018-07-11 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
AU2017230011A1 (en) * 2016-03-11 2018-09-27 2Seventy Bio, Inc. Genome edited immune effector cells
EP4286522A3 (en) * 2016-03-23 2024-02-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins of pd-1 and 4-1bb
WO2019169290A1 (en) * 2018-03-02 2019-09-06 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
EP3774906A1 (en) * 2018-03-28 2021-02-17 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Am. J. Transl. Res.，2015年，Vol. 7，p. 460-473
JNCI Natl. Cancer Inst.，2015年，Vol. 107, djv146，p. 1-10
SCHLENKER, Ramona，Chimeric co-stimulatory receptors as a strategy to improve the performance of T cells in the tumor environment，Dissertation，p. 1-132，2015年

Also Published As

Publication number Publication date
AU2017236069B2 (en) 2021-04-08
CA3017036A1 (en) 2017-09-28
US11365237B2 (en) 2022-06-21
ES2962588T3 (es) 2024-03-20
US20220380435A1 (en) 2022-12-01
NZ745944A (en) 2025-05-30
JP2023078362A (ja) 2023-06-06
AU2017236069A1 (en) 2018-09-20
US20240247046A1 (en) 2024-07-25
EP4286522A3 (en) 2024-02-28
CN109195985A (zh) 2019-01-11
JP7746323B2 (ja) 2025-09-30
US20190106478A1 (en) 2019-04-11
EP3433269C0 (en) 2023-09-27
EP3433269A1 (en) 2019-01-30
CN109195985B (zh) 2022-07-26
EP4286522A2 (en) 2023-12-06
WO2017162797A1 (en) 2017-09-28
JP2019512251A (ja) 2019-05-16
EP3433269B1 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
JP7746323B2 (ja) Ｐｄ－１及び４－１ｂｂの融合タンパク質
JP7460675B2 (ja) Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用
US12162922B2 (en) Enhanced antigen presenting ability of RNA car T cells by co-introduction of costimulatory molecules
CN111836827B (zh) 包含nkg2d结构域的多特异性嵌合受体和其使用方法
KR20170120701A (ko) 면역조절 융합 단백질 및 그 용도
CN110494558B (zh) Gamma delta t细胞和增强其杀肿瘤活性的方法
CN108137670A (zh) Ny-eso-1特异性tcr及其使用方法
WO2022060806A1 (en) Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
WO2023077100A1 (en) T cell receptor recognizing r175h mutation in p53 and its application
JP2024541976A (ja) キメラアダプターポリペプチド
CN114450307A (zh) 基因工程细胞及其用途
HK40109405A (en) Pd1-cd28 fusion proteins and their use in medicine
HK40064520B (en) Pd1-cd28 fusion proteins and their use in medicine
HK40064520A (en) Pd1-cd28 fusion proteins and their use in medicine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190807

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190807

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210518

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230322

R150 Certificate of patent or registration of utility model

Ref document number: 7250519

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150